JP2005503323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005503323A5 JP2005503323A5 JP2002559034A JP2002559034A JP2005503323A5 JP 2005503323 A5 JP2005503323 A5 JP 2005503323A5 JP 2002559034 A JP2002559034 A JP 2002559034A JP 2002559034 A JP2002559034 A JP 2002559034A JP 2005503323 A5 JP2005503323 A5 JP 2005503323A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alkyl
- compound
- administered
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 67
- 150000001875 compounds Chemical class 0.000 claims 43
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 229910052739 hydrogen Inorganic materials 0.000 claims 28
- 239000001257 hydrogen Substances 0.000 claims 28
- 150000002431 hydrogen Chemical class 0.000 claims 28
- 125000000547 substituted alkyl group Chemical group 0.000 claims 28
- 125000003118 aryl group Chemical group 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 19
- 201000011510 cancer Diseases 0.000 claims 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 125000003107 substituted aryl group Chemical group 0.000 claims 14
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 14
- 238000000034 method Methods 0.000 claims 11
- 229930013356 epothilone Natural products 0.000 claims 10
- 150000003883 epothilone derivatives Chemical class 0.000 claims 10
- 238000001990 intravenous administration Methods 0.000 claims 9
- 238000001802 infusion Methods 0.000 claims 8
- 239000000243 solution Substances 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 239000003085 diluting agent Substances 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 239000011593 sulfur Substances 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 238000001035 drying Methods 0.000 claims 4
- 239000002736 nonionic surfactant Substances 0.000 claims 4
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical group O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 claims 3
- 238000007911 parenteral administration Methods 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010022998 Irritability Diseases 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 206010029350 Neurotoxicity Diseases 0.000 claims 2
- 239000008156 Ringer's lactate solution Substances 0.000 claims 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 230000007135 neurotoxicity Effects 0.000 claims 2
- 231100000228 neurotoxicity Toxicity 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229940093181 glucose injection Drugs 0.000 claims 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical group C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000008227 sterile water for injection Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26422801P | 2001-01-25 | 2001-01-25 | |
| US29000601P | 2001-05-11 | 2001-05-11 | |
| PCT/US2002/001813 WO2002058700A1 (en) | 2001-01-25 | 2002-01-22 | Methods of administering epothilone analogs for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005503323A JP2005503323A (ja) | 2005-02-03 |
| JP2005503323A5 true JP2005503323A5 (enrdf_load_stackoverflow) | 2005-12-22 |
| JP4633331B2 JP4633331B2 (ja) | 2011-02-16 |
Family
ID=26950348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002559034A Expired - Fee Related JP4633331B2 (ja) | 2001-01-25 | 2002-01-22 | 癌治療のためのエポチロン類似体の投与方法 |
Country Status (10)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6242469B1 (en) | 1996-12-03 | 2001-06-05 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| AU2008200555C1 (en) * | 2003-03-14 | 2011-12-15 | Novartis Ag | Treatment of proliferative diseases with epothilone derivatives and radiation |
| GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| PA8782301A1 (es) * | 2007-06-01 | 2009-01-23 | Wyeth Corp | Tratamiento de leucemia resistente al imatinte |
| WO2009089138A1 (en) * | 2008-01-04 | 2009-07-16 | Bristol-Myers Squibb Company | Oral administration of ixabepilone |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| US5681846A (en) * | 1995-03-17 | 1997-10-28 | Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
| US6242469B1 (en) * | 1996-12-03 | 2001-06-05 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| EP0995153B1 (en) * | 1997-07-18 | 2001-11-14 | Hewlett-Packard Company, A Delaware Corporation | Format for passing information between devices |
| US6365749B1 (en) * | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| SK287775B6 (sk) * | 1998-02-05 | 2011-09-05 | Novartis Ag | Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| RU2242229C2 (ru) * | 1999-01-19 | 2004-12-20 | Новартис Аг | Применение эпотилонов для лечения рака |
| SK11852001A3 (sk) * | 1999-02-18 | 2002-04-04 | Schering Aktiengesellschaft | Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie |
| UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
-
2002
- 2002-01-22 JP JP2002559034A patent/JP4633331B2/ja not_active Expired - Fee Related
- 2002-01-22 PL PL373727A patent/PL207720B1/pl unknown
- 2002-01-22 AU AU2002245296A patent/AU2002245296B2/en not_active Ceased
- 2002-01-22 CA CA2434526A patent/CA2434526C/en not_active Expired - Lifetime
- 2002-01-22 WO PCT/US2002/001813 patent/WO2002058700A1/en active IP Right Grant
- 2002-01-22 IL IL15657802A patent/IL156578A0/xx not_active IP Right Cessation
- 2002-01-22 HR HR20030677A patent/HRP20030677B1/xx not_active IP Right Cessation
- 2002-01-22 MX MXPA03006412A patent/MXPA03006412A/es active IP Right Grant
- 2002-01-22 RU RU2003126170/15A patent/RU2292202C2/ru active
-
2003
- 2003-07-24 NO NO20033341A patent/NO335119B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100540006C (zh) | 铂衍生物药物制剂 | |
| CZ20003089A3 (cs) | Stabilní roztok oxiplatiny, způsob jeho přípravy, farmaceutický prostředek a použití | |
| US20080161369A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| JP6029808B2 (ja) | 併用療法における（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の使用方法 | |
| JP2005503323A5 (enrdf_load_stackoverflow) | ||
| RU2003126170A (ru) | Способы введения аналогов эпотилона при лечения рака | |
| JPH04505760A (ja) | Ａｚｔの副作用および毒性からの保護方法 | |
| CN108778335B (zh) | 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用 | |
| CN101467967B (zh) | 用于静脉和脑内注射的两元溶液型制剂 | |
| JP2020533318A (ja) | ドセタキセル結合体の医薬組成物及び調製方法 | |
| JP7618235B2 (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法 | |
| CN105769849B (zh) | 一种治疗卵巢癌的药物组合物 | |
| CN105769884B (zh) | 一种治疗肺癌的药物组合物 | |
| JPH01156916A (ja) | 肝疾患治療剤 | |
| KR20060066175A (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 항암 치료보조제 조성물 | |
| HK1073601B (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| JP2004536099A (ja) | チオキサンテノンから成る抗腫瘍製剤 | |
| WO2019079691A1 (en) | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | |
| JPS63104919A (ja) | メンタニルフエノ−ルエチレンオキサイド付加物からなる抗癌剤 | |
| TH71176B (th) | กรรมวิธีสำหรับการเตรียมสูตรผสมของเอโพไธโลนแอนาลอกที่มีหมู่แทนที่อยู่ในโครงสร้างในการเตรียมยาสำหรับการรักษามะเร็ง |